Company intelligence / Profile preview

Atox Lab

Durham, North Carolina, United Statesatoz-labs.com ↗

Ownership: Private
Employees: ~11
Development stage: Other

Overview

Reltecimod, the lead candidate, is an immunomodulatory peptide targeting CD28 to modulate the immune response in severe inflammatory conditions. It has completed Phase 3 clinical trials for necrotizing soft tissue infections and sepsis-associated acute kidney injury but has not yet received regulatory approval. The drug received Orphan Drug designation from both FDA and EMA and Fast Track designation from FDA.

Therapeutic areas: NephrologyInfectious Diseases
Modalities: PeptidesSmall molecule
Industry: Biotech

Partnerships

SR OneLundbeckfond VenturesOrbiMed Advisors

Beyond the preview

Go deeper on Atox Lab.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Atox Lab.

Explore the full profile